Charles River Labs faces a 60% loss due to reduced R&D spending, FDA's phase-out of animal testing, and increased competition ...

We recently published a list of Traders Heavily Sold Down These 10 Stocks on Thursday. In this article, we are going to take ...

Charles River Laboratories International Inc. closed 60.67% short of its 52-week high of $254.15, which the company achieved ...

On Thursday, shares in Charles River Laboratories, a leading contract research organizations that has stirred controversy ...

Shares of Charles River Laboratories International, Inc. (CRL) traded over 3% lower on Friday morning after the U.S. Food and ...

Shares of Charles River Labs (CRL) crashed 28% after the U.S. FDA (Food and Drug Administration) announced plans to phase out the need for ...

After the FDA announced plans to reduce, refine, or potentially replace animal testing requirements for the development of monoclonal ...

FDA introduces a new roadmap to reduce animal testing in monoclonal antibody development using AI models, organoid testing and real-world data to enhance safety and efficiency.

Portuguese biotech FairJourney Biologics has acquired South San Francisco antibody R&D facility from Charles River Labs, ...

This was the stock's third consecutive day of losses.

Shares of Charles River Laboratories International Inc. shed 7.80% to $123.61 Tuesday, on what proved to be an all-around ...